


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-31 (Cancelled).

32. (New) A compound of Formula I:



Formula I

wherein:

n is 0,1, or 2;

R<sub>1</sub> is OH, C<sub>1</sub> to C<sub>12</sub> alkoxy, C<sub>1</sub> to C<sub>12</sub> substituted alkoxy, aryloxy, O-glucosyl or imino;

R<sub>2</sub> is OH, C<sub>1</sub> to C<sub>12</sub> alkoxy, C<sub>1</sub> to C<sub>12</sub> substituted alkoxy, O-glucosyl, oxo, alkyl or imino;

R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, A, B, C, D and E are each independently H, halogen, OH, C<sub>1</sub> to C<sub>12</sub> alkoxy, C<sub>1</sub> to C<sub>12</sub> substituted alkoxy, aryloxy, O-glucosyl, C<sub>1</sub> to C<sub>12</sub> alkyl or C<sub>1</sub> to C<sub>12</sub> substituted alkyl;

wherein R<sub>1</sub> and R<sub>2</sub>, or R<sub>1</sub> and R<sub>4</sub> may form together a lactone which is optionally substituted;

wherein the bonds between C<sub>3</sub>:C<sub>7</sub>, C<sub>4</sub>:C<sub>5</sub>, and C<sub>9</sub>:C<sub>10</sub> may independently be double bonds or single bonds;

provided that at least one of R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, A, B, C, D and E is a halogen; and provided that, if A is the only halogen in the compound, that A is not fluoro;

or a derivative of said formula, wherein the derivative has at least one of the following:

a lower acyl side chain at C<sub>3</sub> (free acid or ester or conjugate), a keto or hydroxy (free hydroxy or ester) moiety at the C<sub>6</sub> carbon, or an n-pentenyl or n-pentyl side chain at C<sub>7</sub>;

including salts, hydrates, solvates, polymorphs, optical isomers, enantiomers, diastereomers, and mixtures thereof.

33. (New) The compound of claim 32, wherein the bond between C<sub>9</sub> and C<sub>10</sub> is a single bond.

34. (New) The compound of claim 32, wherein R<sub>2</sub> is oxo.

35. (New) The compound of claim 32, wherein at least one of R<sub>6</sub> and R<sub>7</sub> is selected from the bromo, iodo, fluoro and chloro.

36. (New) The compound of claim 32, wherein A, B, R<sub>6</sub> and R<sub>7</sub> are selected from bromo, iodo, fluoro and chloro.

37. (New) The compound of claim 32, wherein R<sub>1</sub> is alkoxy.

38. (New) The compound of claim 32, wherein R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are each H.

39. (New) The compound of claim 32, wherein C, D and E are each H.

40. (New) The compound of claim 32, wherein: n is 0; the bonds between C<sub>3</sub>:C<sub>7</sub>, C<sub>4</sub>:C<sub>5</sub>, and C<sub>9</sub>:C<sub>10</sub> are single bonds; R<sub>1</sub> is methoxy; R<sub>2</sub> is oxo; R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, A, B, C, D and E are each H; and R<sub>6</sub> and R<sub>7</sub> are each bromo.

41. (New) The compound of claim 32, wherein: n is 0; the bonds between C<sub>3</sub>:C<sub>7</sub>, C<sub>4</sub>:C<sub>5</sub>, and C<sub>9</sub>:C<sub>10</sub> are single bonds; R<sub>1</sub> is methoxy; R<sub>2</sub> is O bound through a double bond to the carbon in position 6 thereby forming a carbonyl group; R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, C, D and E are each H; and A, B, R<sub>6</sub> and R<sub>7</sub> are each bromo.

42. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as an active ingredient a compound of claim 32.

43. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as an active ingredient a compound of claim 40.

44. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as an active

ingredient a compound of claim 41.

45. (New) A method for reduction of the growth of cancer cells, comprising exposing the cancer cells to a therapeutically effective amount of a compound of claim 32.

46. (New) The method of claim 45 wherein the cancer is selected from the group consisting of: mammalian cancer and human cancer.

47. (New) A method for reduction of the growth of cancer cells, comprising exposing the cancer cells to a therapeutically effective amount of a compound of claim 35.

48. (New) A method for reduction of the growth of cancer cells, comprising exposing the cancer cells to a therapeutically effective amount of a compound of claim 40.

49. (New) A method for reduction of the growth of cancer cells, comprising exposing the cancer cells to a therapeutically effective amount of a compound of claim 41.

50. (New) The method of claim 45, wherein the cancer is selected from the group consisting of carcinoma, sarcoma, adenoma, hepatocellular carcinoma, hepatoblastoma, rhabdomyosarcoma, esophageal carcinoma, thyroid carcinoma, ganglioblastoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphagiosarcoma, synovioama, Ewing's tumor, leimyosarcoma, rhabdotheliosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hematoma, bile duct carcinoma, melanoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell and non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocyoma, medulloblastoma, craniopharyngioma, ependynoma, pinealoma, retinoblastoma, rectal carcinoma, cancer of the thyroid, head and neck cancer, brain cancer, cancer of the peripheral nervous system, cancer of the central nervous system, neuroblastoma, cancer of the endometrium, lymphoproliferative diseases, hematopoietic malignancies including all types of leukemia and lymphoma including: acute myelogenous leukemia, acute myelocytic leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mast cell

leukemia, multiple myeloma, myeloid lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma.

51. (New) A method for the treatment of cancer comprising administering to the subject in need thereof a pharmaceutical composition containing as an active ingredient a therapeutically effective amount of the compound according to claim 32.

52. (New) A method for the treatment of cancer comprising administering to the subject in need thereof a pharmaceutical composition containing as an active ingredient a therapeutically effective amount of the compound according to claim 40.

53. (New) The method according to claim 51, wherein the cancer is selected from the group consisting of carcinoma, sarcoma, adenoma, hepatocellular carcinoma, hepatoblastoma, rhabdomyosarcoma, esophageal carcinoma, thyroid carcinoma, ganglioblastoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endothelirosarcoma, lymphagiosarcoma, synovioama, Ewing's tumor, leimyosarcoma, rhabdothelirosarcoma, colon carcinoma,

pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hematoma, bile duct carcinoma, melanoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell and non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocyoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, retinoblastoma, rectal carcinoma, cancer of the thyroid, head and neck cancer, brain cancer, cancer of the peripheral nervous system, cancer of the central nervous system, neuroblastoma, cancer of the endometrium, lymphoproliferative diseases, hematopoietic malignancies including all types of leukemia and lymphoma including: acute myelogenous leukemia, acute myelocytic leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mast cell leukemia, multiple myeloma, myeloid lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, as well as metastasis of all the above.

54. (New) The method according to claim 52, wherein the cancer is selected from the group consisting of carcinoma, sarcoma, adenoma, hepatocellular carcinoma, hepatoblastoma, rhabdomyosarcoma, esophageal carcinoma, thyroid carcinoma,

ganglioblastoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphagiosarcoma, synovioma, Ewing's tumor, leimyosarcoma, rhabdotheliosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hematoma, bile duct carcinoma, melanoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell and non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocyoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, retinoblastoma, rectal carcinoma, cancer of the thyroid, head and neck cancer, brain cancer, cancer of the peripheral nervous system, cancer of the central nervous system, neuroblastoma, cancer of the endometrium, lymphoproliferative diseases, hematopoietic malignancies including all types of leukemia and lymphoma including: acute myelogenous leukemia, acute myelocytic leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mast cell leukemia, multiple myeloma, myeloid lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, as well as metastasis of all the above.

55. (New) The method of claim 52, wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, skin cancer, colon cancer, lung cancer, pancreatic cancer, lymphoma, leukemia, head and neck cancer, kidney cancer, ovarian cancer, bone cancer, liver cancer, melanoma and thyroid cancer.